|
Alcoholic Intoxication, Chronic
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We found that AGO1 rs595961 (χ(2) = 9.066, p = 0.003; odds ratio [OR] = 0.459, 95% confidence interval [CI]: 0.275-0.768) and AGO2 rs4961280 (χ(2) = 4.111, p = 0.043; OR = 0.590, 95% CI: 0.353-0.986) G alleles have significantly altered the risk for AD, and also there is a significant association of GEMIN4 rs910924 (χ(2) = 5.291, p = 0.021; OR = 1.913, 95% CI: 1.094-3.344) T allele with the risk for AD.
|
25495208 |
2015 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
Biomarker
|
disease |
PSYGENET |
We found that AGO1 rs595961 (χ(2) = 9.066, p = 0.003; odds ratio [OR] = 0.459, 95% confidence interval [CI]: 0.275-0.768) and AGO2 rs4961280 (χ(2) = 4.111, p = 0.043; OR = 0.590, 95% CI: 0.353-0.986) G alleles have significantly altered the risk for AD, and also there is a significant association of GEMIN4 rs910924 (χ(2) = 5.291, p = 0.021; OR = 1.913, 95% CI: 1.094-3.344) T allele with the risk for AD.
|
25495208 |
2015 |
|
Myeloid Leukemia
|
0.310 |
Biomarker
|
disease |
CTD_human |
Investigations revealed that treatment with the newly synthesized drug analogue SH-03[{(7S,7aR,13aS)-9,10-dimethoxy-3,3-dimethyl-7,7a,13,13atetrahydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7-ol}] could induce AGO2-mediated apoptosis in myeloid leukaemia cells via intrinsic apoptotic pathways independent of Dicer.
|
21535412 |
2011 |
|
Myeloid Leukemia
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Further investigations revealed that knock-down of AGO2 by custom-made AGO2 siRNA in HEK-293 cells resulted in silencing of the expression of target genes vascular endothelial growth factor A and histone deacetylase 2, which are known to be involved in the development of myeloid leukaemia.
|
21535412 |
2011 |
|
Malignant mesothelioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.
|
25756049 |
2015 |
|
Leukemia, Monocytic, Chronic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Knock-down of argonaute 2 (AGO2) induces apoptosis in myeloid leukaemia cells and inhibits siRNA-mediated silencing of transfected oncogenes in HEK-293 cells.
|
21535412 |
2011 |
|
Cocaine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction.
|
20643829 |
2010 |
|
Cocaine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction.
|
20643829 |
2010 |
|
Cocaine Dependence
|
0.300 |
Biomarker
|
disease |
CTD_human |
Comparison of miRNAs affected by Ago2 deficiency with miRNAs that are enriched and/or up-regulated in Drd2-neurons in response to cocaine identified a set of miRNAs that are likely to play a role in cocaine addiction.
|
20643829 |
2010 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the contribution of Ago2, the only human Ago protein endowed with nuclease activity, to the function of tumor-suppressor miR-145-5p in breast cancer (BC).
|
30622242 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the breast cancer TMAs, 4 distinct staining intensities were observed (Negative, Weak, Moderate, Strong), with 64.2% of samples stained weak or negatively for Ago2 protein.
|
31324173 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinically, STIM1 and Ago2 expression levels do not correlate with breast cancer progression, however in the basal subtype high STIM1 expression is associated with poorer survival.
|
31506588 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All the results suggest that 4-XL-PPD exhibited remarkable anticancer activity base on inducing apoptosis via generating reactive oxygen species and inhibiting migratory and invasive, which support development of 4-XL-PPD as a potential agent for cancer therapy.
|
31382131 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
According to the obtained results, it can be deduced that dysregulation in transcription of DICER and AGO2, involved in the formation of mature microRNAs in cytoplasm of ALL cancer cells, is a part of the pathological molecular mechanism implicated in the exacerbation of this malignancy.
|
31090156 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results support a model whereby hAgo2:miR-122 complexes alter the structure of the viral 5' terminus and promote formation of the HCV IRES.
|
30941417 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The liver-specific microRNA, miR-122, is an essential host factor for replication of the hepatitis C virus (HCV). miR-122 stabilizes the positive-strand HCV RNA genome and promotes its synthesis by binding two sites (S1 and S2) near its 5' end in association with Ago2.
|
30997501 |
2019 |
|
Hypothyroidism
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The trend in ΔCt values for Ago2-miR-21 and -200c during chemotherapy could predict tumor response to ongoing treatment.
|
30381824 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ginsenoside C<sub>3</sub>C<sub>12</sub>PPD suppressed Lewis and A549 tumor growth in vivo without obvious side effects on body weight and the hematology index.
|
31571900 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPD skin test was positive but tuberculosis antibody test and T-SPOT were negative.
|
30813161 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current results indicate that PPD is a better antigen for antibody-based detection of TB than ESAT-6 and CFP-10.
|
31421107 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinically, STIM1 and Ago2 expression levels do not correlate with breast cancer progression, however in the basal subtype high STIM1 expression is associated with poorer survival.
|
31506588 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the breast cancer TMAs, 4 distinct staining intensities were observed (Negative, Weak, Moderate, Strong), with 64.2% of samples stained weak or negatively for Ago2 protein.
|
31324173 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the contribution of Ago2, the only human Ago protein endowed with nuclease activity, to the function of tumor-suppressor miR-145-5p in breast cancer (BC).
|
30622242 |
2019 |